10.38/s41591-022-02026-4 [DOI] [PMC free article] [PubMed] [Google Scholar] 32.Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al
It is important to note that whilst GLP-1 receptor agonism is well characterised in approved medicines, some mechanistic claims relating to GIP and glucagon receptor activity in humans are based on preclinical data and early clinical findings, and the relative contribution of each pathway in humans is not yet fully elucidated
It's about being the right tool for the right job
In the semaglutide group, no patients in STEP 3 or STEP 4 and 1% of patients in STEP 1 progressed to diabetes while in the placebo group, no patients in STEP 4, 1% of patients in STEP 3, and 3% of patients in STEP 1 progressed to diabetes
After PSM, our study identified significant differences in transaminase levels, recurrence rates, and mortality after adjuvant chemotherapy between breast cancer patients between GSH group and Non-GSH group, indicating that GSH intake may have adverse effects on chemotherapy outcomes
